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Summary: Immunoassays for drug screening are called 'qualitative' or 'semiquantitative' by the manufacturers of
these tests and they urgently recommend the user to verify each result exceeding the recommended cut-off value by a
confirmation test. For therapeutic drug monitoring assays or for the determination of tumour markers or hormones,
similar recommendations are not given, although the same analytical technologies are used for these assays.
A scientific validation of the commonly used cut-off values recommended by the official bodies (e. g. NIDA, DoD)
is unfortunately not described in the accessible scientific literature.
A solution to this problem was sought by evaluating the analytical characteristics of the assay and determining the
diagnostic validity of the test using an immunoassay for the cocaine metabolite äs an example.
Hundred urine samples frorn people suspected of cocaine abuse and 50 urine samples from patients unlikely to
have consumed cocaine were analysed in triplicate with a commercially available fluorescence Polarisation immuno-
assay. From this data we assessed the analytical variance of the assay using the Computer program of Sadler &
Smith (Clin. Chem. 36 (1990), 1346-1350). Using the functions provided, we calculated the limit of detection
(LD) and the lower limit of quantification (LLQ) äs well äs the so-called power of defmition (PD) using a recently
published method (Gautschi et a!., this Journal 31 (1993), 433—440). This procedure is mathematically well defmed,
uses no artificial Standards or calibrators and is in compliance with IFCC recommendations.
A clearly defined assessment of the diagnostic performance of an assay is of utmost importance for the discussion
of adequate decision levels. The influence of different decision levels was demonstrated by assessing the diagnostic
performance of the FPIA assay for benzoylecgonine by calculating the predictive values of a negative and positive
test result for four different decision limits (12, 40, 150, recommended by DoD and 300 g/l, recommended by
NIDA). The respeetive predictive values of the negative results were 0.931, 0.864, 0.704 and 0.661. The predictive
value of a positive test result was uniformly 1.0 for all four cut-offs.
These results are critically discussed wjth respect to the analytical performance of the assay, the socio-economic
and legal consequences of the screening procedure.
Introduction screening and testing people with unexplained, abnor-
~n . ,, , f mal behaviour.There are several reasons for screening people for drug
abuse. The primary uses are however, surveillance of During the past few years, the number of samples sub-
former drug addicts taking part in drug abuse rehabilita- mitted for drug screening has increased dramaticully in
tion programs, routine con the Job' or pre-employment our Institution and can constitute up to 350 urine sam-
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ples a day. New methodological approaches had to be
cvaluated in order to guarantee a rapid turnover äs well
äs a reliable perfomiance of the methods used in drug
testing. The Obligation to confirm the increasing number
of positive results by an alternative (reference) method
(e.g. GC-MS) requires additional personnel and in-
creases costs accordingly.
Modern immunological tests designed for drug screen-
ing using highly automated Systems (e.g. EMIT II,
Syva; TDx, Abbott) are described äs being 'semiquanti-
tative' in the method descriptions supplied by the manu-
facturers, without giving detailed Information on the as-
say performance and how the data given (e. g. limit of
detection) were obtained.
Drug testing is a 'forensic toxicological' analysis, and
äs Peat stated: "... this requires a strict chain of custody,
security of the laboratory, appropriate and adequate
quality control procedures, and the use of legally defen-
sible analytical procedures (1)". However, it is astonish-
ing that for tests whose results have such far-reaching
consequences (false negative äs well äs false positive
results), the performance of the assays, especially the
limit of detection, the limit of quantification and the
threshold concentration have not been evaluated in
studies by using standardized and acceptable mathemati-
cal procedures.
It has been known for many years that the imprecision
of an assay depends upon the concentration of the ana-
lyte, but it was not until the introdüction of radio-
immunoassays that thorough studies have been pub-
lished on the issue (2). Further publications have shown
that this observation is also valid for other procedures
(3). At each analyte concentration a specific imprecision
must therefore be expected and general data cannot be
given.
Despite the fact that several authors (2—4) have pro-
posed the derivation of the analytical limit from a
precision profile, most method descriptions or evahia-
tions use procedures which are statistically not clearly
defmed. To our knowledge, no standardized mathemati-
cal approaches have been used until now to assess the
performance of immunoassays for drugs of abuse.
A standardized mathematical procedure has been de-
scribed in the literature for the evaluation of cyclosporin
(3) and prostate specific antigen (5). Data derived from
human sample material was used to determine the vari-
ance ftmction, which was subsequently applied to deter-
mine the analytical limits. No artificial Standard material
with a matrix different from human samples had to be
used. The characteristics which could be derived from.
the variance function were:
(I) the precision profile,
(II) the limit of detection (LD) and
(III) the limits of quantification (LLQ, ULQ).
Additionally, the power of definition (PD) can be calcu-
lated for every interval of interest (3, 5). The PD allows
one to determine which differences in subsequent values
represent significant (with. p > 0.95) changes at each de-
fmed interval of the analytical ränge.
In this paper we applied a standardized mathematical
procedure for the assessment of the performance of the
cocaine metabolite (benzoylecgoniiie) assay, which is
based on a fluorescence Polarisation immunoassay.
The term 'analytical sensitivity* of the method is criti-
cally discussed both in relation to the consequences of
the definition of the cut-off at different levels and with
respect to the diagnostic sensitivity and specificity of
the screening procedure for the abuse of cocaine. An
alternative procedure for the definition of the threshold
value is proposed.
Materials and Methods
Hundred urine samples of people suspected of cocaine abuse when
entering a drug rehabilitation centre ('patients' group) were ana-
lyzed in triplicates with the Abbott TDx (fluorescence Polarisation
immunoassay, FPIA; Abbott Laboratories, North Chicago). In addi-
tion 50 urine samples from patients from the intensive care unit
were included in the study. These patients were being treated with
several different therapeutic drugs, but an abuse of cocaine could
be excluded ('contfoT group).
The FPIA-method and the Instrument technology has beeil de-;
scribed in detail elsewhere (6). The TDx uses a six-point calibra-
tion curve and prints out quantitative results.
In ofder to calculate the diagnostic sensitivity and specificity of
the procedure, the test results of these two patient groups were
attributed to 13 different classes frorn l .6 to > 400 g/l and plotted
using the Computer program of Abendroth et al. (7). Diagnostic
sensitivity, diagnostic specificity and negative and positive predic-
tive values of the screening procedure for the cocaine metabolite
were calculated for four different cut^off values.
The variance function and the corresponding confidence interval
were derived from triplicate measurements of patient samples using
the computer-prograrn by Sadler & Smith (8). The analytical vari-
ance can be assessed with a minimum of duplicate measurements.
By increasing the number of repetitions, the meaning of each indi-
vidual coefficient of Variation (CV) can be increased. Triplicate
measurements were chosen äs a compromise between the need to
obtain a meaningful CV for every sample and the need to limit the
reagent costs for such a study.
The calculation of the precision profile, the lower limit of quantifi-
cation (LLQ), the limit of detection (LD) and the power of defini-
tion (PD) has been described previously (3). In short: the precision
profile (CV versus analyte concentration) can be derived from the
varianee function. The intersection of a horizontal line — corre-
sponding to an acceptable CV of the method — with the upper
limit of the confidence interval of the precision profile represents
the lower lirnit of the quantification interval (LLQ) [For details see
figure 2 (inset)].
By setting the analyte concentration (U) to zero in the variance
function, the Standard deviation of Jthe blank can be -extrapolated
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and a normal distribution with the respective Standard deviation
can be constructed. Using an iterative mathematical procedure
(Newton-Rawson-procQdure (9)) the adjacent normal distribution
with a defuied overlap of 5% is constructed. The peak value of this
second normal distribution represents the LD. The intersection of
the two normal distributions represent the critical limit (LC)
(fig. 3).
In order to determine the PD for each interval of interest, a series
of normal distributions can be constructed, each overlapping the
previous by e. g. 5%. The PD is a measure for the 'analytical sensi-
tivity' of the method for a distinct interval. The programs for the
calculation of LC, LD, LLQ and PD were developed using the
Computer program 'Microsoft® Excel, version 4.0*.
Results
A. Analytical performance of the cocaine me-
tabolite asssay
Using the PC-program by Sadler & Smith (8) the van-
ance function could be assessed, which describes the
dependence of the variance on the concentration of the
analyte (fig. 1). The function runs s follows: s2 (U)
= (2.050 + 0.0048 (U))3·028. From this variance func-
tion the precision profile could be derived, s shown in
figure 2.
The determination of the lower limit of quantiflcation
(LLQ) was performed according to the procedure shown
in the enlargement in figure 2. The LLQ was determined
to be 39 μ§/1 (10% CV) or 92 μ^ (5% CV). The upper
limit of quantiflcation for this assay is given by the con-
centration of the highest calibrator (1000 μg/l) and not
by the performance of the assay, since the CV at an
analyte concentration of 1000 μg/l is 1.8%.
The coefficients of Variation at analyte concentrations
that will be discussed s potential cut-off limits were
calculated t be: 25.8% (12 μg/l); 8.5% (40 jig/l); 3.1%









Fig. l Analytical variance of triplicate measurements in depen-
dence of the concentration of the analyte (·). The conresponding
regression curve and the confidenee limits were calculated and




Fig. 2 Precision profile corresponding to the plot of the analytical
variance in fig. 1. In the blow up, the determination of the lower
limit of quantiflcation (LLQ) is shown.
5 -10
Cocaine [\ig/\\
Fig. 3 Construction of the normal distribution of the blank and
the adjacent normal distribution following the variance formula and
overlapping the zero-distribution by 5%.
The Standard deviation of the assay at a benzoylecgonine
concentration of zero was calculated by the variance
function (s(0) = 2.96) and used for the construction of
a normal distribution at an analyte concentration of zero
(fig. 3). The intersection of the adjacent normal distribu-
tion, overlapping the 'blank normal distribution' by 5%,
represents the critical limit (LC). At this point the prob-
ability for the presence of the analyte equals the prob-
ability for the absence of the analyte. It was found to be
5.8 μg/l. The limit of detection (LD), where the prob-
ability for the detection of the analyte is ̂  95%, is rep-
resented by the peak value of the second normal distri-
bution. LD was found to be 11.9 μg/l. The CV at this
concentration is 26.0%.
For every interval of the analytical r nge, consecutive
normal distributions, each overlapping the preceeding
by 5%, can be constructed (fig. 4). Tlie number of nor-
mal distributions, which equals the power of de nition
(PD), represents the number of benzoylecgonine values
which can be discriminated with a probability of ̂  95%
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Fig. 4 Assessment of the power of defmition (PD) in the interval of 100 μ§/1 to 500
For details see text.
in a certain interval. In the interval 100-500 μg/l, the
PD is 16, in the interval 400-500 μ§/1, the PD was
found to\be only = 3.
The power of definition at the cut-off value (according
to NIDA = 300 μ§/1 (10)) is shown in the enlarged sec-
tion of figure 4. The values which can be discriminated
from 300 μg/l with p > 95% are < 274.7 μg/l or
> 326.7 μ§/1.
B. Diagnostic performance of the cocaine me-
tabolite screening
The benzyolecgonine values found for the 50 samples
from patients of the intensive care unit who were under
treatment for a wide spectrum of different therapeutic
drugs (population of the 'non-diseased') ranged from 0.0
to 9.8 μg/l, whereas in the cocain addicted population
('diseased') values from 0 μg/l to 586 mg/1 were ob-
served. The distribution of the values in the two popula-
tions is plotted in figure 5. Sensitivity, specificity and
positive and negative predictive values were calculated
for four different cut-off values (tab. 1).
The diagnostic Sensitivity of the screening procedure is
highest (0.926) with a cut-off close to the limit of detec-
tion of the method and decreases dramatically to less
than 0.5 (0.488) with the cut-off recommended by NIDA
(300
With none of the cut-offs used for further calculations,
a false positive classification of a patient resulted and
the specificity of the screening was therefore uniformly
= 1.0.
A consequence of the 100% specificity of the screening
is that the predictive value of the positive result is uni-
formly = 1.0. The predictive value of the negative result
depends on the diagnostic Sensitivity of the procedure
and on the prevalence of the drug abuse. Predictive val-
ues of the negative result for an assumed prevalence of
0.5 are given in table 1.
Discussion
Immunological tests for the quantification of drugs of
abuse were first iiitroduced s radioimmunoassays in
1970 for the determination of morphine in urine (11). A
large scale screening was made possible in m iiy
laboratories only when non-radioactive immunoassays
for drug testing became commercially available and the
degree of a tomation could be significantly improved.
With the rapid technological improvements and the ad-
vances in a tomation technology^ the detection limits for




Fig. 5 Distribution of the cocaine metabolite concentrations in
urine samples of 50 patients of the intensive care unit (filled bars)
and of 100 samples from out-patient clinics for drug addicts (open
bars). The consequences of the choice of different cut-off values
are summarized in tab. 1. Benzoylecgonine concentrations are
given in a logarithmic scale.
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Tab. l Diagnostic sensitivity, specificity and predictive values
for the positive and negative result calculated from the data given





































limits reported for the first immunoassays for the quanti-
fication of cocaine in urine were high (RIA: 0.75 mg/1;
EMIT-dau: 1.6 mg/1; EMIT-st: 0.75 mg/l) (12), whereas
recently issued immunoassays are much more sensitive.
For the FPIA method e. g., a LD of 0.03 mg/1 has been
reported (13). By modifying the calibration procedure
of the Abbott TDx method for the cocaine metabolite a
decrease of the LD to 0.027 mg/1 could be achieved
(14).
The antibody used in the cocaine metabolite assay from
Abbott is highly specific for benzoylecgonine, the pri-
mary urinary metabolite of cocaine. Cross reactivity has
to be expected for cocaine (0.4—0.8%), ecgonine (0.3%)
and ecgonine methylester (<0.1% (13)). Only a few
substances unrelated to cocaine may cause significant
positive interference with immunoassays for benzoylec-
gonine, e. g. phenothiazines (chlorpromazine and thio-
ridazine) and tricyclic antidepressants (amitriptyline).
But these drugs must be present at unlikely concentra-
tions on the order of 100 mg/1 (15-17).
If this model were to be used for group-specific tests
(e. g. benzodiazepines) one or more compounds (metab-
olites) must be selected to assess the performance ofthe
assay. The anälytical result could be related to a major
component for which the antibody used in the test is
specific.
We assessed the anälytical perfonnance ofthe FPlA as-
say using a standardized mathematical procedure for the
determination of the variance function. This procedure
is based on human sample material. No Standards with
artificial rnatrices had to be used. The main problem
in estimating the limit of detection lies in obtaining an
adequate blank (18). This problem can be elegantly
solved by extrapolating the variance function to zero.
From the variance function the critical limit (LC), the
limit of detection (LD) and the lower (and upper) limit
of quantification (LLQ) can be derived according to a
procedure which has been previously described in detail
(3, 5, 19). This procedure is very compatible with IFCC
recommendations (20), which defme the limit of detec-
tion äs a quantity which should be set where "the value
can be distinguished from the blank with a stated prob-
ability"<.
The performance of an anälytical method whose results
may have such severe consequences (not getting a Job,
loss of Job, etc.) should, in our opinion, be assessed
using a highly approved and standardized mathematical
procedure.
Most of the authors and reagent manufacturers who re-
port on the limit of detection either do not describe the
method used to obtain the LD and/or use artificial Stan-
dard material for its determination.
Limits of detection calculated from repetitive measure-
ments of a 'zero-calibrator' by adding 2 Standard devia-
tions (21) or 3 Standard deviations (22) to the mean (ob-
tained by a repetitive measurement of a 'blank' sample),
in our terminology rather represent the critical limit,
where the probability for a false positive estimate is e. g.
^ 5% (2 s) or Ä 1% (3 s). Repetitive measurements of
the zero calibrator deliver at best an imprecision of the
'System noise', which might follow a normal distribu-
tion. Limits based on a certain Standard deviation of
these measurements therefore represent no more than an
exclusion criterion.
In our approach, the limit of detection was set where the
probability for detection of the analyte is ^ 95% (fig.
3). It is, however, important to mention that results in
the ränge of the LD are still burdened with a high im-
precision (26.0% at LD). It is therefore necessary to de-
fine a CV which is acceptable from a diagnostic point
of view and hence to determine the lower limit of quan-
tification, which is significantly different from the LD
(fig. 2).
Most results from drug screening are not given äs quan-
titative values, but rather in a nominal form äs 'positive'
or 'negative'. The decision limit (cut-ofif) used by most
laboratories to obtain this binary result is based on
NIDA specifications origirially issued in 1988 (10).
These cut-off recommendations have not been altered,
despite the fact that detectability (often falsely called
'sensitivity') and specificity ofthe test Systems currently
used have been substantially improved.
As stated by Fuentes-Arderiit, the term 'sensitivity' is
"... most confusing in clinical chemistry ..." (18). The
majority of authors use it when referring to the limit of
detection, in contradiction to international metrological
organizations. According to ISO (23), anälytical sensi-
tivity is "... the change in response of a measuring in-
strument divided by the corresponding change in Stimu-
lus ...". The same is claimed in.other words by IUPAC
(24): "... sensitivity is the slope ofthe anälytical calibra-
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tion curve ...". Sensitivity defmed according to these
recommendations is of great importance for test design,
but useless for test applications under routine conditions.
Here the power of definition is of crucial benefit, be-
cause it includes both the slope of the calibration curve
(the true sensitivity) and the corresponding variability,
e. g. äs confidence intervals.
Recommendations issued by the United States Depart-
ment of Defense in 1993 (directive 1010.1) (25) take the
analytical improvement at least partly into account and
suggest that the cut-off for the cocaine metabolite assay
be lowered to 150 g/l. The level of the chosen cut-off
has a substantial impact on the diagnostic sensitivity of
the screening procedure, äs shown in figure 5 and table
1. Finkle et al. stated that the threshold concentrations
are selected on the basis of 'administrative' and 'pro·-
grammatic' needs (26). In our view, the purpose of
screening for an abuse of drugs should be to detect äs
many recent drug abuses äs possible. The results shown
in table l demonstrate that the diagnostic sensitivity in-
creases substantially if the cut-off is moved to lower
values. By lowering the cut-off to 40 g/l (which is
close to LLQ, if a CV of 10% is accepted) a diagnostic
sensitivity of 0.843 could be achieved and the predictive
value of the negative result could be improved to 0.864
(in a collective with a prevalence for an abuse of cocaine
of 0.50) while the diagnostic specificity and the predic-
tive value of the positive result would remain un-
changed (= 1.0).
As suggested by others (19, 25), we are convinced that
decision levels for the screening for an abuse of cocaine
should be lowered. Hallbach & Guder proposed '... to
use the detection limit äs decision limit ...' (27). Taking
the usually high imprecision of LD into account, we
would recommend the use of LLQ äs the decision limit
(cut-off).
Modern analytical Systems for drug screenings are based
on the same principles äs assays for the determination
of hormones, tumour markers and therapeutic drugs. All
of these assays are established äs true quantitative meth-
ods for diagnostic pufposes. Nevertheless, the tnanufac-
turers label their drug-screening assays äs 'qualitative'
or even äs 'semiquantitative' tests, äs is usually done for
urine test Strips. But äs stated by Dybkaer (28) "... these
terms are ambiguous and give insufficient Information
..." and should therefore be avoided.
Very much care is taken to avoid false positive test re-
sults. The users of the test kits are urged to confinn each
positive result by a so called 'confifmation test', despite
the fact that imprecision äs well äs detectability of the
recommended analytical Systems (GC, HPLC) is in
many cases worse compared to modern immunological
Systems, especially in the case of the cocaine metabolite
assäy where the immunological test is highly specific
(29). The medical or forensic screening of (suspected)
drug äddicts involves a special difficulty in so far äs if
an abuse of drugs is stated, portentous psychological,
social, economical and judiciäl consequences miglit re-
sult. False results (especially false positives) may even
involve the liability for compensation. This might ex-
plain why mänufacturers of Systems for the screening
for drugs of abuse advise caution when interpreting test
results and do not object to the use of outdated cut-
off values.
But it seems to be important to emphasise the fact that
official documents urge drug testing laboratories not
only to minimize their number of false positive test re-
sults by using confirmation procedures, but also state
that the number of false negative results has to be kept
< 10% (10).
The data presented hefe demonstrate that — using the
NID A cut-off value — almost half of the urine samples
with benzoylecgonine concentrations well above LD are
classified äs 'negative'. This kind of false negative re-
sults can only be minimized if the decision limit is con-
siderably lowered and adapted to the actual analytical
state of the art.
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